The mechanism of HCC sensitization to anti-PD-L1 and anti-VEGFA therapy by LDRT likely relies on the recruitment of stem-like progenitor CD8+ T(p)ex located in the draining lymph nodes and transported to the tumoral core through the chemokine (C-X-C motif) ligand 10/chemokine (C-X-C motif) receptor 3 (CXCL10/CXCR3) axis. Here, VEGFA is linked to hepatocellular carcinoma.